|Awarded On||August 19, 2020|
|Title||Enhancing Cytarabine Response Through SAMHD1 Inhibition|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Dimitri Ivanov|
*Pending contract negotiation
Leukemias are the most common pediatric cancers accounting for approximately 30% of total diagnoses. Although remarkably high cure rates have now been achieved for acute lymphoblastic leukemia (ALL), the risk of refractory or recurrent disease is significantly elevated in patients of Hispanic descent, a major demographic served by the UT Health San Antonio. The goal of the proposed study is to address this medical need by exploring a new paradigm for treatment of refractory/recurrent ALL and acute myeloid leukemia (AML). The study seeks to enhance the efficacy of cytarabine, a first-line treatment for AML and refractory/recurrent ALL, using a novel strategy suggested by two recent seminal st...